Gene Therapies Target Neurodegenerative Diseases
A growing pipeline of gene therapy candidates aimed at treating neurodegenerative diseases has prompted new guidance.
Much of gene therapy development is targeting neurodegenerative diseases, among other difficult-to-treat indications. Responding to a growing pipeline of gene therapy candidates, FDA released a new draft guidance in January 2021, Human Gene Therapy for Neurodegenerative Diseases, focused on gene therapies being developed to treat neurodegenerative diseases. The new draft guidance focuses on product development, preclinical testing, and clinical trial design as well as discusses marketing approval pathways for investigational gene therapy products for neurodegenerative disease indications.
Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 12–13
Citation
When referring to this article, please cite it as F. Mirasol, “Gene Therapies Target Neurodegenerative Diseases," BioPharm International Regulatory Sourcebook eBook (March 2021).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
